SCHEMBL4584724

SCHEMBL4584724

Brc1ccc2c(-c3ccccc3)c3ccc(Br)cc3c(-c3ccccc3)c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
MAPK1 P28482 2/20 0.48
DCLK1 O15075 1/20 0.47
PRKD3 O94806 1/20 0.47
MAP4K4 O95819 1/20 0.47
CHEK2 O96017 1/20 0.47
CSF1R P07333 1/20 0.47
FER P16591 1/20 0.47
CDK2 P24941 1/20 0.47
MARK3 P27448 1/20 0.47
FLT4 P35916 1/20 0.47
FLT3 P36888 1/20 0.47
MAPK9 P45984 1/20 0.47
CSNK1D P48730 1/20 0.47
CLK2 P49760 1/20 0.47
CSNK2A1 P68400 1/20 0.47
CSNK1G2 P78368 1/20 0.47
MAP4K2 Q12851 1/20 0.47
STK3 Q13188 1/20 0.47
CAMK2B Q13554 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL824275 1.00 ALDH1A1 (0.48) ALDH1A1MAPK1DCLK1PRKD3MAP4K4
SCHEMBL30136959 0.98 ALDH1A1 (0.46) ALDH1A1MAPK1DCLK1PRKD3MAP4K4
SCHEMBL389776 0.98 ALDH1A1 (0.46) ALDH1A1MAPK1DCLK1PRKD3MAP4K4
SCHEMBL28924402 0.94 ALDH1A1 (0.54) ALDH1A1MAPK1DCLK1PRKD3MAP4K4
SCHEMBL12791336 0.94 ALDH1A1 (0.54) ALDH1A1MAPK1DCLK1PRKD3MAP4K4
SCHEMBL13777187 0.93 DCLK1 (0.50) ALDH1A1MAPK1DCLK1PRKD3MAP4K4
SCHEMBL4572765 0.91 ALDH1A1 (0.44) ALDH1A1MAPK1DCLK1PRKD3MAP4K4
SCHEMBL13978583 0.91 ALDH1A1 (0.44) ALDH1A1MAPK1DCLK1PRKD3MAP4K4
SCHEMBL15895326 0.91 ALDH1A1 (0.48) ALDH1A1MAPK1DCLK1PRKD3MAP4K4
SCHEMBL13777183 0.90 ALDH1A1 (0.54) ALDH1A1MAPK1DCLK1PRKD3MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293381-B2 excellent power and luminance efficiencies in conjunction with a long service life; 2,7,9,10-tetraphenylanthracene SFC CO., LTD. (KR) 2012-10-23 US disclosed
US-8293381-B2 excellent power and luminance efficiencies in conjunction with a long service life; 2,7,9,10-tetraphenylanthracene SFC CO., LTD. (KR) 2012-10-23 US disclosed
US-8293381-B2 excellent power and luminance efficiencies in conjunction with a long service life; 2,7,9,10-tetraphenylanthracene SFC CO., LTD. (KR) 2012-10-23 US disclosed
US-20080152950-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME SFC CO., LTD. (KR) 2008-06-26 US disclosed
US-20080152950-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME SFC CO., LTD. (KR) 2008-06-26 US disclosed
US-20080152950-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME SFC CO., LTD. (KR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080152950-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME C1S, C1R, AOC2 ALDH1A1 163/4885MAPK1 778/4885DCLK1 2462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.